Cancer Research Technology and Teva Pharmaceutical Industries Limited Form R&D Alliance for Cancer DNA Damage Response Drugs

Published: Sep 16, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

JERUSALEM & LONDON--(BUSINESS WIRE)--Cancer Research Technology Ltd. (CRT), Cancer Research UK’s technology development arm, and Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) have signed a multi-project alliance agreement to research and develop first-in-class cancer drugs that modulate DNA damage and repair response (DDR) processes in cancer cells.

Help employers find you! Check out all the jobs and post your resume.

Back to news